Drug
Teropavimab clinical trials
Also written 3BNC117-LS and GS-5423.
- studies test it
- 13
- open now
- 2
- in phase 3
- 2
- first study started
- 2017
Keep track of what changes. Save the teropavimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 3
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 9
Gilead Sciences (4) · Rockefeller University (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2) · International AIDS Vaccine Initiative (1)
Often tested with
Tested in the same studies.
Zinlirvimab (9) · Lenacapavir (4) · Antiretroviral Therapy (1) · Nogapendekin alfa inbakicept (1)
Studies
Open first, then newest update. How each study uses teropavimab is read from its arms, and is right about nine times in ten.
Testing it · 13
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyRecruitingPhase 3Gilead SciencesNCT07682961Written as Teropavimab
- Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensRecruitingPhase 3Gilead SciencesNCT07683000Written as Teropavimab
- A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral TherapyActive, not recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05612178Written as 3BNC117-LS
- Antiretrovirals Combined With Antibodies for HIV-1 Cure In AfricaActive, not recruitingPhase 2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT06205602Written as 3BNC117-LS
- Pausing Antiretroviral Treatment Under Structured EvaluationCompletedPhase 1Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT06031272Written as 3BNC117-LS-J
- 3BNC117-LS First-in-Human Phase 1 StudyCompletedPhase 1Rockefeller UniversityNCT03254277Written as 3BNC117-LS
- A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionActive, not recruitingPhase 2Gilead SciencesNCT05729568Written as Teropavimab
- 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)CompletedPhase 1Rockefeller UniversityNCT05245292Written as 3BNC117-LS
- Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African AdultsCompletedPhase 1/2International AIDS Vaccine InitiativeNCT04173819Written as 3BNC117-LS-J
- Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionCompletedPhase 1Gilead SciencesNCT04811040Written as Teropavimab
- Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATIWithdrawnPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05079451Written as 3BNC117-LS
- 3BNC117-LS and 10-1074-LS in Viremic HIV-infected IndividualsCompletedPhase 1Rockefeller UniversityNCT04250636Written as 3BNC117-LS
- First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LSCompletedPhase 1Rockefeller UniversityNCT03554408Written as 3BNC117-LS
Given in every arm · 3 — teropavimab is usual care beside what is tested
- bNAbs and Anti-PD-1 in HIVNot yet recruitingPhase 2Ole Schmeltz SøgaardNCT07820813Written as 3BNC117-LS
- Combination Vaccination and Broadly Neutralising Antibody Therapy in HIVRecruitingPhase 2University of OxfordNCT07054931Written as GS-5423
- Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1SuspendedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06071767Written as GS-5423
Codes
What other systems call teropavimab · ClinicalTrials.gg INT015297
- UNII (FDA) 6MQW0DZ370TEROPAVIMABOne source FDA
- NCI Thesaurus C184837TeropavimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6MQW0DZ370 | TEROPAVIMAB | One source FDA |
| NCI Thesaurus | C184837 | Teropavimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.